Dasiglucagon: Diabetes

A glucagon analog for the treatment of Type 1 diabetes

Dasiglucagon is an investigational glucagon analog that is stable in solution.

People with type 1 diabetes have both an absolute deficiency of insulin and impaired release of glucagon, especially during hypoglycemia. Balancing the effect of these two key hormones is important to ensure stable and healthy blood glucose levels.

Zealand Pharm Lab Part 1 BF3I7979
Type 1 diabetes
PROGRAM Dasiglucagon: Diabetes
Phase 2

Development status

Bi-Hormonal Artificial Pancreas Systems:

We are developing a pre-filled dasiglucagon cartridge intended for use in Bihormonal Artificial Pancreas (BHAP) systems. Dasiglucagon is in clinical development for use with these BHAP systems containing both insulin and dasiglucagon. 

Mini-Dose Pen: 

We believe dasiglucagon administered in a mini-dose pen may have potential for the treatment of exercise-induced hypoglycemia in people living with type 1 diabetes and for people who suffer from meal-induced hypoglycemia following gastric bypass surgery (post bariatric hypoglycemia, or PBH).

Four investigator-initiated clinical trials conducted in collaboration with Zealand evaluated mini-dose dasiglucagon to support a potential development program. 

Additionally, a Phase 2 trial in PBH conducted in an out-patient setting has been completed and met the primary endpoint.

Dasiglucagon is an investigational compound whose safety and efficacy  has not been evaluated or approved for marketing by any regulatory authority for the potential applications described.

Related scientific publications

All scientific publications
  • Diabetes Care

    Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial

  • Diabetalogia

    Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial

  • Diabetes Care

    Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

  • Diabetes Care

    Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study

Collaboration for BHAP

We have a non-exclusive collaboration with Beta Bionics, developer of the Bihormonal iLet® Bionic Pancreas (iLet Duo™), a pocket-sized, dual chamber (insulin and dasiglucagon), autonomous, glycemic control system. The iLet Duo™ is an investigational device that is limited to investigational use only.

The iLet® Bionic Pancreas platform is designed to use adaptive, self-learning control algorithms together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body’s natural ability to maintain tight glycemic control.

  • Learn more about our partnerships
  • Beta Bionics

    Learn about clinical trials of dasiglucagon in diabetes

    Type 1 Diabetes

    More about the disease area

    Type 1 diabetes (T1D) is a chronic autoimmune disease where the body attacks and kills the cells that would produce insulin. Without insulin, the body cannot regulate blood sugar.

  • Learn more
  • ZEALAND AR 2018 Anders1028 B3A5969